Availability of yttrium-90 from strontium-90: A nuclear medicine perspective

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 10, 2012, Pages 621-641

  Chakravarty, Rubel ^a   Dash, Ashutosh ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

90Sr 90Y generator; hepatocellular carcinoma; neuroendocrine tumors; non Hodgkins lymphoma (NHL); radionuclide therapy; rheumatoid arthritis; somatostatin receptors; Yttrium 90

Indexed keywords

ALPHA FETOPROTEIN MONOCLONAL ANTIBODY Y 90; ANGIOPEPTIN Y 90; AVIDIN Y 90; BIOTIN Y 90; BISPECIFIC ANTIBODY Y 90; BOMBESIN Y 90; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY Y 90; CD20 ANTIGEN; CLIVATUZUMAB TETRAXETAN Y 90; EPRATUZUMAB Y 90; GLUCOSE REGULATED PROTEIN DERIVATIVE Y 90; IBRITUMOMAB TIUXETAN; IODINE 131; LUTETIUM 177; MICROSPHERE; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; RITUXIMAB; SAMARIUM 153; SIR SPHERES; SOMATOSTATIN RECEPTOR; STRONTIUM 90; THERA SPERE; TRACE METAL; UNCLASSIFIED DRUG; URANIUM 235; YTTRIUM 86; YTTRIUM 90; YTTRIUM CITRATE Y 90; YTTRIUM SILICATE Y 90; ZIRCONIUM 90;

ARTHRITIS; BONE CELL; BREAST CANCER; CLINICAL PROTOCOL; COLON CANCER; COLUMN CHROMATOGRAPHY; DIAGNOSTIC TEST; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MANUFACTURE; DRUG PURITY; ELECTRON; ELUTION; GAMMA SPECTROMETRY; HEMATOPOIETIC TISSUE; HEMOPHILIA; HOSPITAL PHARMACY; HUMAN; ION EXCHANGE; ION EXCHANGE CHROMATOGRAPHY; IRRADIATION; ISOTOPE LABELING; LIVER CANCER; LUNG CANCER; LYMPHOMA; MOLECULARLY TARGETED THERAPY; NEUTRON ACTIVATION ANALYSIS; NONHODGKIN LYMPHOMA; NUCLEAR FUEL REPROCESSING; NUCLEAR MEDICINE; PANCREAS CANCER; PAPER CHROMATOGRAPHY; PAPER ELECTROPHORESIS; PARTICULATE MATTER; POSITRON EMISSION TOMOGRAPHY; PRECIPITATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RADIOISOTOPE DECAY; RADIOISOTOPE THERAPY; REVIEW; RHEUMATOID ARTHRITIS;

HUMANS; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS; STRONTIUM RADIOISOTOPES; YTTRIUM RADIOISOTOPES;

EID: 84870774227     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1285     Document Type: Review

References (177)

1. Lewington VJ. Targeted radionuclide therapy for neuroendocrinetumours. Endocr-Relat Cancer 2003;10:497.
2. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR.Therapeutic radionucides: Production and decay propertyconsiderations. J Nucl Med 1991;32:174.
3. Therapeutic Radionuclide Generators: 90Sr/90Y and188W/188Re generators. IAEA Technical Report Series No.470, Vienna: IAEA, 2009.
4. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinatingradiometals of Copper, Gallium, Indium, Yttrium,and Zirconium for PET and SPECT imaging ofdisease. Chem Rev 2010;110:2858.
5. Correia JDG, Paulo A, Raposinho PD, Santos I. Radiometallatedpeptides for molecular imaging and targetedtherapy. Dalton Trans 2011;40:6144.
6. Del VS, Zannetti A, Fonti R, et al. Nuclear imaging incancer theranostics. Q J Nucl Med Mol Imaging2007;51:152.
7. Abbasi IA, Zaidi JH, Arif M, et al. Measurement of fissionneutron spectrum averaged cross sections of some thresholdreactions on zirconium: Production possibility of nocarrier-added 90Y in a nuclear reactor. Radiochim Acta2006;94:381.
8. Production of Long Lived Parent Radionuclides for Generators:68Ge, 82Sr, 90Sr and 188W. IAEA Radioisotopes andRadiopharmaceuticals Series No. 2, Vienna: IAEA, 2010.
9. Wester DW, Steele RT, Rinehart DE, et al. Large-scale purificationof 90Sr from nuclear waste materials for productionof 90Y, a therapeutic medical radioisotope. Appl RadiatIsot 2003;59:35.
10. Ramanujam A, Dhami PS, Chitnis RR, et al. Separation ofStrontium-90 from PUREX High Level Waste and Developmentof 90Sr/90Y Generator. BARC report 2000/E/009,BARC India, 2000.
11. Beard SJ, Moore RL. Large-scale recovery and purificationof fission products. In: Stevenson CE, Mason EA, GreskyAT, eds., Progress in Nuclear Energy (Series III), ProcessChemistry, Vol. 4. London: Pergamon Press, 1969:645.
12. Buckingham JS. Waste Management Technical Manual,ISO-100. Richland, WA: Isochem, Inc., 1967.
13. Hosaka TY, Sevigny GJ, Schlender MH. High level liquidwaste treatment process: Reducing risk and capitalizing onhigh value isotopes. Proceedings of the Waste ManagementSpectrum'96, Seattle 1996, American Nuclear Society,Washington, DC, 1996:2257.
14. Healy TV, Carter PE, Brown PE. The extraction of strontiumfrom fission product solutions. In: Bruce FR, Fletcher JM, HymanHH, Katz JJ, eds., Progress in Nuclear Energy (Series III),Process Chemistry, Vol. 1. London: Pergamon Press, 1956:363.
15. Bray LA. The Recovery and Purification of Multi-KilocurieQuantities of Fission Product Strontium by Cation Exchange,Rep. HW-70998, Richland, WA: Hanford AtomicProducts Operation, 1961.
16. Orth RJ, Kurath DE. Review and Assessment of Technologiesfor the Separation of Strontium from Alkaline andAcidic Media, Rep. PNL-9053, Richland, WA: PacificNorthwest National Laboratory, 1994.
17. Horwitz EP, Dietz ML, Fisher DE. SREX: A new process forthe extraction and recovery of strontium from acidic nuclearwaste streams. Solv Extr Ion Exch 1991;9:1.
18. Romanovsky VN. Management of accumulated high levelwaste at the Mayak Production Association in the RussianFederation. Proceedings of an International Conference onIssues and Trends in Radioactive Waste Management, heldat International Atomic Energy Agency, Vienna (December9-13, 2002), p. 359-372.
19. Romanovsky VN. US-Russian cooperative program in researchand development of chemical separation technologies.In: Choppin GC, Khankhasayev M, Plendi HS, eds.,Chemical Separations in Nuclear Waste Management: TheState of the Art and a Look to the Future. Rep. DOE/EM-0591, Columbus: Battelle, 2001:57.
20. Lumetta GJ, Wester DW, Morrey JR, Wagner MJ. Preliminaryevaluation of chromatographic techniques for theseparation of radionuclides from high level radioactivewaste. Solv Extr Ion Exch 1993;11:663.
21. Lange G, Herrmann G, Strassmann F. Preparation ofstrontium-90 free yttrium-90 by electrolysis. J Inorg NuclChem 1957;4:146.
22. Wike JS, Guyer CE, Ramey DW, Phillips BP. Chemistry forcommercial-scale production of yttrium-90 for medical research.Appl Radiat Isot 1990;41:861.
23. Lee TW, Ting G. Study on the separation of carrier freeYttrium-90 from Sr-90. Isotopenpraxis 1991;27:269.
24. Dietz LM, Horwitz EP. Improved chemistry for productionof yttrium-90 for medical applications. Appl Radiat Isot1992;43:1093.
25. Hsieh BT, Ting G, Hsieh HT, Shen LH. Preparation ofcarrier-free yttrium-90 for medical applications by solventextraction chromatography. Appl Radiat Isot 1993;44:1473.
26. Dash A, Bhattacharya PK. Preparation of a 90Sr-90Y generatorusing zirconium antimonate. Appl Radiat Isot 1994;45:415.
27. Castillo AX, Pérez-Malo M, Isaac-Olivé K, et al. Productionof large quantities of 90Y by ion-exchange chromatographyusing an organic resin and a chelating agent. Nucl Med Biol2010;37:935.
28. Naik PW, Jagasia P, Dhami PS, et al. Separation of carrierfree90Y from 90Sr by SLM technique using D2EHPA in Ndodecaneas carrier. Sep Sci Technol 2010;45:554.
29. Castillo AX, Isaac-Olivé K, González EC, et al. An adaptedpurification procedure to improve the quality of 90Y forclinical use. Radiochim Acta 2009;97:739.
30. Shapovalov VV, Nerozin NA, Smetanin EY, Mel'NichenkoNA. A semicountercurrent extraction generator of 90Y.Radiochemistry 2009;51:507.
31. Lee JS, Park UJ, Son KJ, Han HS. One column operation for90Sr/90Y separation by using a functionalized-silica. ApplRadiat Isot 2009;67:1332.
32. Dhara S, Sarkar S, Basu S, Chattopadhyay P. Separation ofthe 90Sr-90Y pair with cerium (IV) iodotungstate cation exchanger.Appl Radiat Isot 2009;67:530.
33. Dhami PS, Naik PW, Dudwadkar NL, et al. Studies on thedevelopment of a two stage SLM system for the separationof carrier-free 90Y using KSM-17 and CMPO as carriers. SepSci Technol 2007;42:1107.
34. Bray LA, Wester DW. Method of Separation of Yttrium-90from Strontium-90. U.S. Patent 5, 512, 256, April 30, 1996.
35. Bray LA. Method for separating and purifying Yttrium-90from Strontium-90. U.S. Patent US2006/0018813 A1, Jan.26, 2006.
36. Horwitz EP, Hines JJ. Method for Isolating and Purifying90Y from 90Sr in Multi-Curie Quantities. U.S. Patent 6,309,614 B1, Oct. 30, 2001.
37. Betenekov ND, Sharygin LM, Brown RW. Sr-90/Y-90radionuclide generator for production of high quality Y-90solution. U.S. Patent US 7,101,484 B2, Sep. 5, 2006.
38. Mushtaq A. Inorganic ion-exchangers: Their role in chromatographicradionuclide generators for the decade 1993-2002. J Radioanal NuclChem 2004;262:797.
39. Kawashima T. Separation of carrier-free 90Y from 90Sr bycation exchange in a methanol-ammonium acetate medium.Int J Appl Radiat Isot 1969;20:806.
40. Skraba WJ, Arino H, Kramer HH. A new 90Sr/90Y radioisotopegenerator. Int J Appl Radiat Isot 1978;29:91.
41. Chinol M, Hnatowich DJ. Generator-produced Yttrium-90for radioimmunotherapy. J Nucl Med 1987;28:1465.
42. Du J, Chinol M, Savonen A, Hiltunen J. Simple and safeproduction of yttrium-90 from a new type of 90Sr/90Y generator.Radiochim Acta 2005;93:111.
43. Malja S, Schomacker K, Malja E. Preparation of 90Y by the90Sr-90Y generator for medical purpose. J Radioanal NuclChem 2000;245:403.
44. Huntley MJ. Use of Chelex-100 for Selectively Removing Y-90 from Its Parent Sr-90. U.S. Patent 5, 494,697, Feb. 27, 1996.
45. Bilewicz A. Separation of 90Y from 90Sr on crystalline antimonicacid. Radiochim Acta 1995;69:137.
46. Sylvester P. Ion Exchange Materials for the Separation of90Y from 90Sr. U.S. Patent 6,974,563 B2, Dec. 13, 2005.
47. Sylvester P. Novel Ion Exchange Materials for the Separationof 90Y from 90Sr. U.S. Patent 2003/0231994 A1, Dec. 18, 2003.
48. Lee JS, Han HS., Park UJ, et al. Adsorbent, PreparationMethod Thereof and Sr-90/Y-90 Generator Using the Same.U.S. Patent US/2011/0020206 A1, Jan. 27, 2011.
49. Chakraborty R, Chattopadhyay P. Sodium titaniumsilicateas ion exchanger: Synthesis, characterization and applicationin separation of 90Y from 90Sr. J Radioanal Nucl Chem2012;294:31.
50. Roy K, Mohapatra PK, Rawat N, et al. Separation of 90Yfrom 90Sr using zirconium vanadate as the ion exchanger.Appl Radiat Isot 2004;60:621.
51. Chakraborty R, Dhara S, Basu S, Chattopadhyay P. Quinolinephosphomolybdateas ion exchanger: Synthesis,characterization, and application in separation. J RadioanalNucl Chem 2011;287:55.
52. Peppard DF, Mason GW, Moline SW. The use of dioctylphosphoric acid extraction in the isolation of carrier-free90Y, 140La, 144Ce, 143Pr, and 144Pr. J Inorg Nucl Chem1957;132:141.
53. Mirza MY. A new method for the carrier-free production of90Y from 90Sr-90Y mixture and 89Sr from neutron-irradiatedY2O3. Anal Chim Acta 1968;40:229.
54. Kodina GE, Korpusov GV, Filyanin AT. Production ofhigh-purity 90Y on specially developed centrifugal semicounterflowextractors. Radiochemistry 2002;44:62.
55. Srank J, Melichar F, Filyanin AT, et al. Preparation of 90YCl3radiopharmaceutical precursor for nuclear medicine usingtechnology of centrifugal extractors. Appl Radiat Isot2010;68:2163.
56. Chuang JT, Lo JG. The solvent extraction of carrier-free 90Y.J Radioanal Nucl Chem 1995;189:307.
57. Wood DJ, Elshani S, Du HS, et al. Separation of 90Y from90Sr by solvent extraction with ionizable crown ethers. AnalChem 1993;65:1350.
58. Horwitz EP, Schulz WW. Solvent extraction in the treatmentof acidic high-level liquid waste: Where do we stand?In: Bond AH, Dietz ML, Rogers RD, eds., Metal-Ion Separationand Preconcentration: Progress and Opportunities,ACS Symposium Series 716, Vol. 716, WashingtonD.C.: American Chemical Society, 1999:20.
59. Vanura P, Makrlik E. Separation of microamounts of yttriumfrom strontium by using nitrobenzene solution ofsodium dicarbollylcobaltate in the presence of 18-crown-6. JRadioanal Nucl Chem 2002;251:499.
60. Makrlik E, Vanura P. Separation of microamounts ofyttrium from strontium by using sodium dicarbollylcobaltate,Slovafol 909 and ethylenediamine-N, N, N¢,N¢-tetraacetic acid in the water-nitrobenzene extractionsystem. J Radioanal Nucl Chem 2006;268:645.
61. Vanura P, Makrlik E, Vobecky M. Separation of yttriumfromstrontium in the aqueous phase of the water/nitrobenzeneextraction system. J Radioanal Nucl Chem 2003;256:171.
62. Vanura P, Jedináková-Kŕ-zová V. Radiochemical 90Sr/90Ygenerator using two phase heptachloro-bis-1,2-dicarbollylcobaltatecrown extraction system. Czech J Phys 2003;53:A459.
63. Dutta S, Mohapatra PK, Manchanda VK. Separation of 90Yfrom 90Sr by a solvent extraction method using N,N,N¢,N¢-tetraoctyl diglycolamide(TODGA) as the extractant. ApplRadiat Isot 2011;69:158.
64. Dutta S, Raut DR, Mohapatra PK. Role of diluents on theseparation of 90Y from 90Sr by solvent extraction and supportedliquid membrane using T2EHDGA as the extractant.Appl Radiat Isot 2012;70:670.
65. Malinin AB, Kurchatova LN, Tronova IN, et al. A Yttrium-90 generator giving high radiochemical purity. Radiokhimiya1984;26:500.
66. Achuthan PV, Dhami PS, Kannan R, et al. Separation ofcarrier-free 90Y from high level waste by extraction chromatographictechnique using 2-Ethyl hexyl-2-ethyl hexylphosphonic acid (KSM-17). Sep Sci Technol 2000;35:261.
67. Horwitz EP, Chiarizia R, Dietz ML. A novel strontium selectiveextraction chromatographic resin. Solvent Extr IonExc 1992;10:313.
68. Horwitz EP, Dietz LM. Process for the Separation andPurification of Yttrium-90 for Medical Applications. U.S.Patent 5,368,736, Nov. 29, 1994.
69. Horwitz EP, Dietz ML, Fisher DE. Separation and preconcentrationof strontium from biological, environmental,and nuclear waste samples by extraction chromatographyusing a crown ether. Anal Chem 1991;63:522.
70. Chuang JT, Lo JG. Extraction chromatographic separationof carrier-free 90Y from 90Sr/90Y generator by crown ethercoated silica gels. J Radioanal Nucl Chem 1996;204:83.
71. Lo JG, Chuang JT. Method and Generation for Generating90Y from 90Sr. U.S. Patent 5,508,011, April 16, 1996.
72. Dutta S, Mohapatra PK, Raut DR, Manchanda VK. Chromatographicseparation of carrier free 90Y from 90Sr using adiglycolamide based resin for possible pharmaceutical applications.J Chromatogr A 2011;1218:6483.
73. Koda Y. Separation of pure 90Y from a 90Sr-90Y mixture byco-precipitation with ferric hydroxide. J Inorg Nucl Chem1963;25:733.
74. Friedlander G, Kennedy JW, Macias ES, Miller JM. Techniquesin nuclear chemistry. In: Nuclear and Radiochemistry,3rd edition. New York: John Wiley and Sons,1981:287.
75. Kanapilly GM, Newton GJ. A new method for the separationof multicurie quantities of 90Y from 90Sr. Int J ApplRadiat Isot 1971;22:567.
76. Ramanujam A, Achuthan PV, Dhami PS, et al. Separationof carrier-free 90Y from high level waste by supported liquidmembrane using KSM-17. J Radioanal Nucl Chem2001;247:185.
77. Happel S, Streng R, Vater P, Ensinger W. Sr/Y separationby supported liquid membranes based on nuclear trackmicro filters. Radiat Meas 2003;36:761.
78. Kandwal P, Ansari SA, Mohapatra PK, Manchanda VK.Separation of carrier free 90Y from 90Sr by hollow fibersupported liquid membrane containing bis(2-ethylhexyl)phosphonic acid. Sep Sci Technol 2011;46:904.
79. Van Dijk H, Ijsseling FP, Loman H. Rapid paperelectrophoreticseparation of strontium from yttrium,caesium from barium and thallium from lead and bismuthin radioactive mixtures. Anal Chim Acta 1962;27:563.
80. Hamaguchi H, Ikeda N, Kawashima T. Isolation of carrierfree yttrium from the radioactive strontium-yttrium systemby electrochemical deposition. Bunseki Kagaku 1958;7:243.
81. Qureshi IH, Meinke WW. Radiochemical separation ofstrontium by amalgam exchange. Talanta 1963;10:737.
82. Chakravarty R, Pandey U, Manolkar RB, et al. Developmentof an electrochemical 90Sr-90Y generator for the separationof 90Y suitable for targeted therapy. Nucl Med Biol2008;35:245-252.
83. Kamadhenu Electrochemical 90Sr/90Y generator, Model KA01 Operating Manual. Germany: Isotope TechnologiesDresden, 2010.
84. USP monographs: Yttrium Y-90 Ibritumomab TiuxetanInjection. www.pharmacopeia.cn/v29240/usp29nf24s0-m89430.html. Accessed on April 4, 2012.
85. Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodieslabeled with yttrium-90. J Nucl Med 1985;26:503.
86. Schomä cker K, Malja S, Cuci T, Fisher T. Some aspects ofthe Sr-90-Y-90 generator production and development of anew quality control method. J Nucl Med 1997;38:103.
87. Rösch F, Beyer GJ, Schä fer G, Poser D. Quantitative electrophoreticseparation of strontium and yttrium. AnnualReport 1989, ZFK Rossendorf, Germany 1990; 711:66.
88. Venkatesh M, Pandey U, Dhami PS, et al. Complexationstudies with 90Y from a novel 90Sr-90Y Generator. RadiochimActa 2001;89:1.
89. Salutsky ML, Kirby HW. Preparation and half life of carrier-free Yttrium-90. Anal Chem 1955;27:567.
90. Vanura P, Jedináková-Kr?́-zová V, Vobecký M. The use ofliquid scintillation spectrometry for the determination ofradionuclidic purity of 90Y from a radiochemical 90Y/90Srgenerator. J Radioanal Nucl Chem 2006;267:501.
91. Vapirev EI, Grozev PA, Botsova L, Hristova AV. Betaspectoscopicseparation of 90Sr, 90Y and 89Sr with a scintillationdetector. J Radioanal Nucl Chem 1993;173:293.
92. Doering RF, Tucker WD, Stang Jr., LG. A rapid method forthe detection of 90Sr contamination in 90Y. J Inorgan NuclChem 1960;15:215.
93. Bonardi ML, Martano L, Groppi F, Chinol M. Rapid determinationof 90Sr impurities in freshly generator eluted90Y for radiopharmaceutical preparation. Appl Radiat Isot2009;67:1874.
94. Pandey U, Dhami PS, Jagesia P, et al. A novel extractionpaper chromatography (EPC) technique for the radionuclidicpurity evaluation of 90Y for clinical use. AnalChem 2008;80:801.
95. Scientific discussion for the approval of Ytracis. Report.www.emea. europa.eu/humandocs/PDFs/EPAR/ytracis/655702en6.pdf. Accessed on April 4, 2012.
96. Strelow FEW, Rethemeyer R, Bothma CJC. Ion exchangeselectivity scales for cations in nitric acid and sulfuric acidmedia with a sulfonated polystyrene resin. Anal Chem1965;37:106.
97. IAEA Health Physics and Radiological Health Handbook.Vienna: IAEA, 1990.
98. Reshetin VP. Estimation of radioactivity levels associatedwith a 90Sr dirty bomb event. Atmos Environ 2005;39:4471.
99. News and Terrorism: A fact sheet from the National Academiesand the U.S. Department of Homeland Security(www.nae.edu/File.aspx?id = 11317). Accessed on April 4,2012.
100. What is non-Hodgkin lymphoma? American Cancer Society.Available at: www.cancer.org/Cancer/Non-HodgkinLymphoma/DetailedGuide/non-hodgkinlymphoma- what-isnon-hodgkin-lymphoma. Accessed on April 4, 2012.
101. Zahm S. A case control study of non-Hodgkin's lymphjomaand the herbicide 2,4-dichlorophenoxyacetic acid(2, 4-D) inEastern Nebraska. Epidemiology 1990;1:349.
102. American Cancer Society. Types of non-Hodgkin lymphoma.Available at:www.cancer.org/Cancer/Non-HodgkinLymphoma/DetailedGuide/non-hodgkinlymphoma- typesof-non-hodgkin-lymphoma. Accessed on April 4, 2012.
103. Treatment option overview for adult non-Hodgkin lymphoma.National Cancer Institute. Available at: www.cancer.gov/cancertopics/pdq/treatment/adultnon- hodgkins/HealthProfessional/page4. Accessed on April 5, 2012.
104. Illidge T. Radioimmunotherapy in non-Hodgkin's lymphoma:Can it change the course of the disease? HematolMeet Rep 2007;1:52.
105. Sioka C, Fotopoulos A. Immunotherapy and radioimmunotherapyfor non-Hodgkin's Lymphoma. CancerTher 2008;6:311.
106. Emmanouilides C. Review of 90Y-ibritumomab tiuxetan asfirst-line consolidation radio-immunotherapy for B-cellfollicular non-Hodgkin's lymphoma. Cancer Manage Res2009;2:131.
107. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial ofIDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20 + B-cell non-Hodgkin's lymphoma. JClin Oncol 1999;17:3793.
108. Witzig TE, Gordon LI, Cabanillas F, et al. Randomizedcontrolled trial of Yttrium-90-labeled Ibritumomab Tiuxetanradioimmunotherapy versus Rituximab Immunotherapy for patients with relapsed or refractory low-grade, follicular, ortransformed B-Cell non-hodgkin's lymphoma. J Clin Oncol2002;20:2453.
109. Witzig TE, White CA, Flinn IW. Zevalin radioimmunotherapyof rituximab-refractory follicular non-Hodgkin's lymphoma. Blood 2000;96:507a.
110. Witzig TE, Gordon LI, Wiseman GA. Reduced dose Zevalinis safe and effective in patients with relapsed or refractory,low grade, follicular or CD20 + transformed B cell non-Hodgkin's lymphoma (L/F/T NHL) and mild thrombocytopenia.Blood 2000;96:728a.
111. Jensen RT, Norton JA. Carcinoid tumors and the carcinoidsyndrome. In: DeVita VT, Heilman S, Rosenburg SA, eds.,Cancer: Principles and Practice of Oncology, 5th edition.Cambridge, MA: Blackwell Scientific Publications,1996: 1706.
112. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatinreceptor sst1-sst5 expression in normal and neoplastichuman tissues using receptor autoradiography withsubtype-selective ligands. Eur J Nucl Med 2001;28:836.
113. Gulenchyn KY, Yao X, Asa SL, et al. Radionuclide therapyin neuroendocrine tumours: A systematic review. ClinOncol 2012;24:294.
114. Walter T, Brixi-Benmansou H, Lombard-Bohas C, CadiotG. New treatment strategies in advanced neuroendocrinetumours. Digest Liv Dis 2012;44:95.
115. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targetedradionuclide therapy with 90Y-DOTATOC in patientswith neuroendocrine tumors. Anticancer Res 2006;26:703.
116. Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclidetherapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC)in neuroendocrine tumours. Eur J Nucl Med MolImaging 2004;31:1038.
117. Graham MM, Menda Y. Radiopeptide imaging and therapyin the United States. J Nucl Med 2011;52:56S.
118. Ambrosini V, Fani M, Fanti S, et al. Radiopeptide imagingand therapy in Europe. J Nucl Med 2011;52:42S.
119. Sowa-Staszczak A, Pach D, Kunikowska J, et al. Efficacyand safety of 90Y-DOTATATE therapy in neuroendocrinetumours. Pol J Endocrinol 2011;62:392.
120. de Jong M, Bakker WH, Breeman WA, et al. Pre-clinicalcomparison of [DTPA0, Tyr3]octreotide and [DOTA0,D-Phe1, Tyr3] octreotide as carriers for somatostatinreceptor-targeted scintigraphy and radionuclide therapy.Int J Cancer 1998;75:406.
121. Otte A, Jermann E, Behe M, et al. DOTATOC: A powerfulnew tool for receptor mediated radionuclide therapy. Eur JNucl Med 1997;24:792.
122. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC:First clinical results. Eur J Nucl Med 1999;26:1439.
123. Waldherr C, Pless M, Maecke HR, et al. Tumor responseand clinical benefit in neuroendocrine tumors after 7.4 GBq(90)Y-DOTATOC. J Nucl Med 2002;43:610.
124. Valkema R, Pauwels S, Kvols LK, et al. Survival and responseafter peptide receptor radionuclide therapy with[90Y-DOTA0,Tyr3]octreotide in patients with advancedgastroenteropancreatic neuroendocrine tumours. SeminNucl Med 2006;36:147.
125. Iten F, Muller B, Schindler C, et al. Response to [90yttrium-DOTA]-TOC treatment is associated with long-term survivalbenefit in metastasized medullary thyroid cancer: Aphase II clinical trial. Clin Cancer Res 2007;13:6696.
126. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics.CA-Cancer J Clin 2005;55:74.
127. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer:Worldwide incidence and trends. Gastroenterology2004;127:S5.
128. Riaz A, Lewandowski RJ, Kulik LM, et al. Complicationsfollowing radioembolization with Yttrium-90 microspheres:A comprehensive literature review. J Vasc IntervRadiol 2009;20:1121.
129. Deleporte A, Flamen P, Hendlisz A. State of the art: Radiolabeledmicrospheres treatment for liver malignancies.Expert Opin Pharmacother 2010;11:579.
130. Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma:Pilot trial of treatment with Y-90 microspheres.Radiology 1989;172:857.
131. Anderson JH, Goldberg JA, Bessent RG, et al. Glass yttrium-90 microspheres for patients with colorectal livermetastases. Radiother Oncol 1992;25:137.
132. Shepherd FA, Rotstein LE, Houle S, et al. A phase I doseescalation trial of yttrium-90 microspheres in the treatmentof primary hepatocellular carcinoma. Cancer 1992;70:2250.
133. Sato K, Lewandowski RJ, Bui JT, et al. Treatment ofunresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): Assessment of hepatic arterialembolization. Cardiovasc Intervent Radiol 2006;29:522.
134. Riaz A, Lewandowski RJ, Kulik L, Salem R. Yttrium-90radioembolization using TheraSphere in the managementof primary and secondary liver tumors. Q J Nucl Med MolImaging 2009;53:311.
135. Cianni R, Urigo C, Notarianni E, et al. Selective internalradiation therapy with SIR-spheres forthe treatment ofunresectable colorectal hepatic metastases. Cardiovasc InterventRadiol 2009;32:1179.
136. Van De Wiele C, Defreyne L, Peeters M, Lambert B. Yttrium-90 labelled resin microspheres for treatment of primaryand secondary malignant liver tumors. Q J Nucl MedMol Imaging 2009;53:317.
137. TheraSphere yttrium-90 microspheres [package insert].Kanata, ON, Canada: MDS Nordion. (www.accessdata.fda.gov/cdrh-docs/pdf/H980006c.pdf). Accessed onApril 4, 2012.
138. SIR-Spheres yttrium-90 microspheres [package insert].Lane Cove, Australia: Sirtex Medical. (www.sirtex.com/files/SSL-US-09.pdf). Accessed on April 4, 2012.
139. Ehrhardt GJ, Day D. Therapeutic use of Y-90 microspheres.Nucl Med Biol 1987;14:233-242.
140. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectablehepatocellular carcinoma with intrahepatic 90Ymicrospheres.J Nucl Med 2000;41:1673.
141. Lau WY, Leung WT, Ho S, et al. Treatment of inoperablehepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: A phase I and II study. Br J Cancer1994;70:994.
142. Murthy R, Habbu A, Salem R. Trans-arterial hepaticradioembolisation of yttrium-90 Microspheres. BiomedImaging Interv J 2006;2:e43.
143. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microspheretherapy for hepatic malignancy: Devices, indications,technical considerations, and potential complications.RadioGraphics 2005;25:S41.
144. Gates VL, Atassi B, Lewandowski RJ, et al. Radioembolizationwith Yttrium-90 microspheres: Review of anemerging treatment for liver tumors. Future Oncol 2007;3:73.
145. Salem R, Hunter RD. Yttrium-90 microspheres for thetreatment of hepatocellular carcinoma: A review. Int J RadiatOncol Biol Phys 2006;66:S83.
146. Salem R, Thurston KG. Radioembolization with Yttrium-90microspheres: A state-of-the-art brachytherapy treatmentfor primary and secondary liver malignancies Part 3:Comprehensive literature review and future direction. JVasc Interv Radiol 2006;17:1571.
147. Schneider P, Farahati J, Reiners C. Radiosynovectomy inrheumatology, orthopedics, and hemophilia. J Nucl Med2005;46:48S.
148. Modder G. Radiosynoviorthesis-Involvement of NuclearMedicine in Rheumatology and Orthopaedics. WarlichDruck und Verlagsges. Meckenheim, Germany: MbH, 1995.
149. Ishido C. On the effect of radiothoriums on the joints.Radiotherapy 1924;15:537.
150. Fellinger K, Schmid J. The local treatment of the rheumaticdisorders. Vienna J Inn Med 1952;33:351.
151. Delbarre F, Cayla J, Menkes C, et al. Synoviorthesis withradioisotopes. Presse Med 1968;76:1045.
152. Gumpel JM, Beer TC, Crawley JCW, Farran HEA. Yttrium90 in persistant synovitis of the knee- A single centrecomparison. The retention and extra-articular spread offour 90Y radiocolloids. Br J Radiol 1975;48:377.
153. Bayly RJ, Peacegood JA, Peake SC. 90Y ferric hydroxidecolloid. Ann Rheum Dis 1973;32:10.
154. Pandey U, Ketaki B, Sarma HD, et al. Bioevaluation of 90Ylabeledparticles in animal model of arthritis. Ann NuclMed 2009;23:333.
155. Pandey U, Mukherjee A, Chaudhary PR, et al. Preparationand studies with 90Y-labelled particles for use in radiationsynovectomy. Appl Radiat Isot 2001;55:471.
156. European Association of Nuclear Medicine. EANM Procedureguidelines for radiosynovectomy. Eur J Nucl Med2003;30:BP12.
157. Markou P, Chatzopoulos D. Yttrium-90 silicate radiosynovectomytreatment of painful synovitis in knee osteoarthritis.Results after 6months. Hell JNuclMed 2009;12:33-36.
158. Williams ED, Caughey DE, Hurley PJ, John MB. Distributionof yttrium 90 ferric hydroxide colloid and gold 198colloid after injection into knee. Ann Rheum Dis1976;35:516.
159. Davis MA, Chinol M. Radiopharmaceuticals for radiationsynovectomy: Evaluation of two Yttrium-90 particulateagents. J Nucl Med 1989;30:1047.
160. Brecelj J, Gmeiner-Stopar T, Jevsek M, et al. Colloidal 90Yused for radiation synovectomy decreases the viability ofchondrocytes in human cadaveric samples. Nucl MedCommun 2007;28:704.
161. Taylor WJ, Corkill MM, Rajapaske CNA. A retrospectivereview of Yttrium-90 synovectomy in the treatment of kneearthritis. Br J Rheumatol 1997;36:1100.
162. Kampen WU, Voth M, Pinkert J, Krause A. Therapeuticstatus of radiosynoviorthesis of the knee with yttrium [90Y]colloid in rheumatoid arthritis and related indications.Rheumatology 2007;46:16.
163. Jahangier ZN, Jacobs KMG, Bijlsma JWJ, Lafeber FPJG.Radiation synovectomy with yttrium-90 for persisting arthritishas direct harmful effects on human cartilage thatcannot be prevented by co-administration of glucocorticoids:An in vitro study. Ann Rheum Dis 2006;65:1384.
164. Deutsch W, Brodack JW, Deutsch KF. Radiosynovectomyrevisited. Eur J Nucl Med 1993;20:1113.
165. Heuft-Dorenbosch LLJ, de Vet HCW, van der Linden S.Yttrium radiosynoviorthesis in the treatment of knee arthritisin rheumatoid arthritis: A systematic review. AnnRheum Dis 2000;59:583.
166. Menkes C, Go LA, Verrier P, Delbarre F. A contolled trial ofintra-articular yttrium-90, osmic acid and triamcinolonehexacetonide in rheumatoid arthritis. Proceedings of theXIV Congress Rheumatology, San Francisco, Maryland:Lippincott Williams and Wilkins, 1977:614.
167. Boerbooms AM, Buijs WC, Danen M, et al. Radiosynovectomyin chronic synovitis of the knee joint in patientswith rheumatoid arthritis. Eur J Nucl Med 1985;10:446.
168. Yates DB, Scott JT, Ramsey N. Double-blind trial of 90Y forchronic inflammatory synovitis of the knee. RheumatolRehabil 1979;18:46.
169. Carrasquillo JA, White JD, Paik CH, et al. Similarities anddifferences in 111In-and 90Y-Labeled 1B4M-DTPA AntiTacMonoclonal antibody distribution. J Nucl Med 1999;40:268.
170. Hemert FJ, Sloof GW, Schimmel KJM, et al. Radiopharmaceuticalmanagement of 90Y/111In labeled antibodies:Shielding and quantification during preparationand administration. Ann Nucl Med 2006;20:575.
171. Liu S, Pietryka J, Ellars CE, Edwards DS. Comparison ofYttrium and Indium complexes of DOTA-BA and DOTAMBA:Models for 90Y-and 111In-labeled DOTA-biomoleculeconjugates. Bioconjugate Chem 2002;13:902.
172. Walrand S, Flux GD, Konijnenberg MW, et al. Dosimetry ofyttrium-labelled radiopharmaceuticals for internal therapy:86Y or 90Y imaging? Eur J Nucl Med Mol Imaging2011;38:S57.
173. Buchholz HG, Herzog H, Forster GJ, et al. PET imagingwith yttrium-86: Comparison of phantom measurementsacquired with different PET scanners before and after applyingbackground subtraction. Eur J Nucl Med Mol Imaging2003;30:716.
174. Avila-Rodriguez MA, Selwyn RG, Converse AK, NicklesRJ. 86Y and 89Zr as PET imaging surrogates for 90Y: Acomparative study. AIP Conf Proc 2006;854:45.
175. Arrichiello C, Aloj L, Mormile M, et al. Feasibility ofbremsstrahlung dosimetry for direct dose estimation inpatients undergoing treatment with 90Y-ibritumomabtiuxetan. Eur J Nucl Med Mol Imaging 2012;39:956.
176. Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J NuclMed 2009;50:1427.
177. Wu SY, Chang TK, Kuo JW, et al. Evaluation of 68Ga/111In-SIR-Spheres as a novel PET/SPECT imaging surrogate of90Y-SIR-Spheres. J Nucl Med 2010;51:1553.